Table 2 Protocols for stage IA and IB NSCLC
First author (Ref) | Prescribed dose (Gy/fraction) | Reference point | Isocenter dose (Gy/fraction) | Calculation algorithm/inhomogeneity correction |
|---|---|---|---|---|
Nagata (2) | 48/4 | isocenter | 48/4 | PBC /yes |
Onimaru (3) | 40 or 48/4 | isocenter | 40 or 48/4 | Clarkson or superposition /yes |
Koto (4) | 45/3 or 60/8 | isocenter | 45/3 or 60/8 | BPL /yes |
Baumann (5) | 45/3 | 67% at PTV periphery | 67.2/3 | PBC /yes |
Takeda (6) | 50/5 | 100% at PTV periphery | 62.5/5 | MG superposition /yes |
Fakris (7) | 60/3* 66/3** | 80% at least 95% of PTV | at least 79.4/3* at least 86.8/3** | unspecified /no |
Our study | 48/4* 52/4** | isocenter | 48/4* 52/4** | PBC /yes |